

20010962-123300
JC07 Rec'd PCT/PTO 13 DEC 2001
10/009792

HYLEE60.001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Lee, et al.)	Group Art Unit: Unk
)	
Appl. No.	:	Unknown)	
)	
Filed	:	Herewith)	
)	
For	:	ESCHERICHIA COLI STRAIN)	
		SECRETING HUMAN)	
		GRANULOCYTE COLONY)	
		STIMULATING FACTOR (G-CSF))	
)	
Examiner	:	Unknown)	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Preliminary to examination on the merits, please amend the above-captioned U.S. application as follows:

ABSTRACT

An abstract of the invention is submitted herewith on a separate sheet.

IN THE SPECIFICATION:

On page 1 of the Specification, after the Title of the Invention and before the BACKGROUND OF THE INVENTION statement starting on line 1, please insert ---This is the U.S. National Phase under 35 U.S.C. § 371 of International Application PCT/KR01/00549, filed March 31, 2001, which claims priority of KR 2000/17052, filed March 31, 2000.---

IN THE SEQUENCE LISTING:

Please replace the original Sequence Listing with the attached replacement Sequence Listing, pages 1-9. Please insert the replacement Sequence Listing after page 18 of the present

JC07 Rec'd PCT/PTO 13 DEC 2001

10/009792

Appl. No. : Unknown
Filed : Herewith

specification. Please consecutively renumber all pages following the insertion of the replacement Sequence Listing.

IN THE CLAIMS

Please amend the claims as follows:

Claim 2. (amended) The recombinant plasmid vector of claim 1, wherein the oligopeptide has an amino acid sequence of isoleucine-glutamic acid-glycine-arginine (Ile-Glu-Gly-Arg; from residue 10-13 of SEQ ID NO: 1) at the C-terminus.

REMARKS

The claims have been amended to conform with the rules of practice before the U.S. Patent and Trademark Office and to correct typographical errors. The specification has been amended to recite the International Application and priority application. As a result of this preliminary amendment, Claim 2 has been amended. Accordingly, Claims 1-10 are presented for examination. No new matter is being added herewith.

Also enclosed with this Amendment are: (1) a paper copy of the replacement Sequence Listing, and (2) a computer readable version of the replacement Sequence Listing. The Preliminary Amendment directs entry of the paper copy of the replacement Sequence Listing into the application. In view of the foregoing, the application is believed to fully comply with the Sequence Listing Disclosure requirements.

The specific changes to the specification and the amended claims are shown on a separate set of pages attaches hereto and entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this Amendment. On this set of pages, insertions are underlined and deletions are struck through.

VERIFICATION UNDER 37 C.F.R. § 1.821 (f) & (g)

All of the sequences in the attached Sequence Listing were included in the application as filed in the PCT application. Pursuant to 37 C.F.R. § 1.821 (g), no new matter is being added herewith. As required under 37 C.F.R. § 1.821 (f), I hereby verify that the data on the enclosed disk and the paper copies of the Sequence Listing are identical.

Appl. No. : Unknown
Filed : Herewith

JC07 Rec'd PCT/PTO 13 DEC 2001

10/009792

Conclusion

Should there be any questions concerning this application, the Examiner is invited to contact the undersigned agent at the telephone number appearing below.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: November 13, 2001

By: Che S. Chereskin
Che Swyden Chereskin, Ph.D.
Registration No. 41,466
Agent of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404

Appl. No. : Unknown
Filed : Herewith


JC07 Rec'd PCT/PTO 13 DEC 2001
10/009792

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claim 2 has been amended as follows:

Claim 2. (amended) The recombinant plasmid vector of claim 1, wherein the oligopeptide has an amino acid sequence of isoleucine-~~glutamic~~-glutamic acid-glycine-arginine (Ile-Glu-Gly-Arg; from residue 10-13 of SEQ ID NO: 1) at the C-terminus.

H:\DOCS\CSC\CSC-2632.DOC
111201



LEE, et al. 001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lee, et al.

Appl. No. : 10/009,792

Filed : November 13, 2001

For : ESCHERICHIA COLI STRAIN
SECRETING HUMAN
GRANULOCYTE COLONY
STIMULATING FACTOR
(G-CSF)

Examiner : Unknown

) Group Art Unit Unknown

) I hereby certify that this correspondence and
) all marked attachments are being deposited
) with the United States Postal Service as
) first-class mail in an envelope addressed to:
) United States Patent and Trademark Office,
) P.O. Box 2327, Arlington, VA 22202, on

10/25/02

(Date)

Mincheol Kim, Reg. No. 51,306

SUPPLEMENTAL PRELIMINARY AMENDMENT and
SEQUENCE SUBMISSION STATEMENT

United States Patent and Trademark Office
PO Box 2327
Arlington, VA 22202

Dear Sir:

Prior to examination on the merits, please amend the above-referenced application as follows:

IN THE SEQUENCE LISTING:

Please replace the Sequence Listing with the substitute Sequence Listing attached hereto.

REMARKS

This is in response to the Notification of Missing Requirements Under 35 U.S.C. § 371 in the United States Designated/Elected Office mailed August 2, 2002. Applicants have replaced the Sequence Listing with the Sequence Listing attached hereto. In the substitute Sequence Listing, the name of the Applicants (as required by United States practice), the Application number, and the prior applications have been updated. Amino acid numbering is provided. Sequences 1-27 have not been amended. Thus, no new matter has been added by the amendments made in the Sequence Listing.

Appl. No. : 10/009,792
Filed : November 13, 2001

Sequence Submission Statement

I hereby state that the amendments, made in accordance with 37 C.F.R. §1.825(a), included in the substitute Sequence Listing submitted herewith are supported in the application as filed. I hereby state that the substitute Sequence Listing does not include new matter.

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(b), is the same as the substitute Sequence Listing.

Conclusion

In view of the foregoing, Applicants submit that the present application is now in condition for examination. Should any questions remain concerning this application, the Examiner is invited to contact the undersigned at the telephone number appearing below.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 10/25/02

By: 

Mincheol Kim
Registration No. 51,306
Agent of Record
Customer No. 20,995
(619) 235-8550

O:\DOCS\MCM\MCM-3073.DOC
101802